By continuing to browse the site you are agreeing to our use of cookies and similar tracking technologies described in our privacy policy.

Concordance between SVR4, SVR12, and SVR24 in HCV-infected patients who received fixed-dose combination sofosbuvir/velpatasvir in phase 3 clinical trials (abstract 983). Presented at: International Liver Congress; June 23-26, 2021; virtual

Year of Publication

2021

Authors